Table 2.
Cross-resistance among β-lactams and β-lactamase inhibitor combinations when tested against P. aeruginosa isolates collected from CF patients (2018–19)
| Antimicrobial | Percentage susceptible by resistant subset (no. of isolates)a |
||||
|---|---|---|---|---|---|
| MEM-NS (74) | TZP-NS (54) | CAZ-NS (53) | C/T-NS (26) | CAZ/AVI-NS (11) | |
| MEM | 0.0 | 20.4 | 17.0 | 3.8 | 9.1 |
| TZP | 41.9 | 0.0 | 15.1 | 3.8 | 27.2 |
| CAZ | 40.5 | 16.7 | 0.0 | 3.8 | 0.0 |
| C/T | 66.2 | 63.0 | 52.8 | 0.0 | 18.2 |
| CAZ/AVI | 86.5 | 85.2 | 79.2 | 65.4 | 0.0 |
CAZ, ceftazidime; MEM, meropenem; TZP, piperacillin/tazobactam; C/T, ceftolozane/tazobactam; AVI, avibactam; NS, non-susceptible.
a
Isolates were categorized as non-susceptible based on CLSI criteria.